74
|
279
|
5eh0A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
92
|
302
|
5ew8A |
Fibroblast growth factor receptor 1 in complex with jnj-4275693 |
86
|
322
|
5edqA |
Egfr kinase (t790m/l858r) with inhibitor compound 15: ~{n}-(7-chloranyl-1~{h}-indazol-3-yl)-7,7-dimethyl-2-(1~{h}-pyrazol-4-yl)-5~{h}-furo[3,4-d]pyrimidin-4-amine |
110
|
355
|
5etiA |
Structure of dead kinase mapk14 |
76
|
279
|
5ap3A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
121
|
376
|
5eqyA |
Crystal structure of choline kinase alpha-1 bound by 5-[(4-methyl-1,4-diazepan-1-yl)methyl]-2-[4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]benzenecarbonitrile (compound 65) |
78
|
280
|
5ap0A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
84
|
280
|
5ei8A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
95
|
302
|
5e8vA |
Tgf-beta receptor type 2 kinase domain (e431a,r433a,e485a,k488a,r493a,r495a) |
93
|
309
|
4zseA |
Crystal structure of egfr 696-1022 t790m/v948r, crystal form ii |
102
|
301
|
5e8sA |
Tgf-beta receptor type 1 kinase domain (wt) |
103
|
350
|
5ekoA |
Crystal structure of mapk13 complex with inhibitor |
88
|
290
|
5e1eA |
Human jak1 kinase in complex with compound 30 at 2.30 angstroms resolution |
76
|
262
|
4zs0A |
Human aurora a catalytic domain bound to sb-6-oh |
78
|
259
|
5e9eA |
Crystal structure of the alpha-kinase domain of myosin-ii heavy chain kinase a in complex with amp-pnp |
92
|
297
|
5eydA |
Crystal structure of c-met in complex with amg 337 |
76
|
279
|
5ap2A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
89
|
351
|
5etaA |
Structure of mapk14 with bound the kim domain of the toxoplasma protein gra24 |
77
|
280
|
5ap4A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
116
|
341
|
4zslA |
Mitogen activated protein kinase 7 in complex with inhibitor |
94
|
304
|
5e92A |
Tgf-beta receptor type 2 kinase domain (e431a,r433a,e485a,k488a,r493a,r495a) in complex with amppnp |
79
|
273
|
5eolA |
Crystal structure of human pim-1 kinase in complex with a macrocyclic quinoxaline-pyrrolodihydropiperidinone inhibitor |
94
|
304
|
5e91A |
Tgf-beta receptor type 2 kinase domain (e431a,r433a,e485a,k488a,r493a,r495a) in complex with 3-amino-6-[4-(2- hydroxyethyl)phenyl]-n-[4-(morpholin-4-yl)pyridin-3-yl] pyrazine-2-carboxamide |
88
|
323
|
5em5A |
Egfr kinase domain mutant "tmlr" with pyridone compound 2: 4-[2-(4-chlorophenyl)ethylamino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}-pyridine-3-carboxamide |
64
|
257
|
5e4hA |
Crystal structure of apoenzyme alpha-kinase domain of myosin-ii heavy chain kinase a |
74
|
279
|
5ei2A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
92
|
309
|
5eg3A |
Crystal structure of the activated fgf receptor 2 (fgfr2) kinase domain in complex with the csh2 domain of phospholipase c gamma (plcgamma) |
83
|
289
|
5f20A |
Structure of tyk2 with inhibitor 4: 3-azanyl-5-(2-methylphenyl)-7-(1-methylpyrazol-3-yl)-1~{h}-pyrazolo[4,3-c]pyridin-4-one |
93
|
322
|
5edrA |
Egfr kinase (t790m/l858r) with inhibitor compound 27: ~{n}-(1~{h}-indazol-3-yl)-7,7-dimethyl-2-(2-methylpyrazol-3-yl)-5~{h}-furo[3,4-d]pyrimidin-4-amine |
91
|
298
|
5ew3A |
Human vascular endothelial growth factor receptor 2 (kdr) kinase domain in complex with aal993 |
82
|
279
|
5ap6A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
119
|
378
|
5eqeA |
Crystal structure of choline kinase alpha-1 bound by [4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]methanamine (compound 11) |
102
|
303
|
5e8wA |
Tgf-beta receptor type 1 kinase domain (t204d) in complex with staurosporine |
120
|
344
|
4zsjA |
Mitogen activated protein kinase 7 in complex with inhibitor |
100
|
303
|
5e8zA |
Tgf-beta receptor type 1 kinase domain (t204d) in complex with 3-amino-6-[4-(2-hydroxyethyl)phenyl]-n-[4-(morpholin-4-yl)pyridin-3-yl]pyrazine-2-carboxamide |
90
|
323
|
5em8A |
Egfr kinase domain with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}-pyridine-3-carboxamide |
73
|
304
|
5e7rA |
Crystal structure of tl10-81 bound to tak1-tab1 |
84
|
279
|
5ei6A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
88
|
301
|
5e1sA |
The crystal structure of insr tyrosine kinase in complex with the inhibitor bi 885578 |
72
|
282
|
5ehlA |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
77
|
267
|
5f4nA |
Multi-parameter lead optimization to give an oral chk1 inhibitor clinical candidate: (r)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (cct245737) |
82
|
264
|
5dt0A |
Aurora a kinase in complex with jnj-7706621 in space group p6122 |
75
|
297
|
5angA |
Crystal structure of cdk2 in complex with 7-hydroxy-4-(morpholinomethyl)chromen-2-one processed with the crystaldirect automated mounting and cryo-cooling technology |
81
|
264
|
5drdA |
Aurora a kinase in complex with atp in space group p6122 |
80
|
264
|
5dr6A |
Aurora a kinase in complex with aa30 and jnj-7706621 in space group p6122 |
117
|
464
|
5dvrA |
Crystal structure of tgcdpk1 from toxoplasma gondii complexed with gw780159x |
81
|
297
|
5aniA |
Crystal structure of cdk2 in complex with 6-chloro-7h-purine processed with the crystaldirect automated mounting and cryo-cooling technology |
88
|
297
|
5amnA |
The discovery of 2-substituted phenol quinazolines as potent and selective ret kinase inhibitors |
84
|
263
|
5dpvA |
Aurora a kinase in complex with aa35 and jnj-7706621 in space group p6122 |
79
|
298
|
5ankA |
Crystal structure of cdk2 in complex with 2,4,6-trioxo-1-phenyl- hexahydropyrimidine-5-carboxamide processed with the crystaldirect automated mounting and cryo-cooling technology |